Trial Profile

Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination With Cabozantinib/Nivolumab for Patients With Metastatic Renal Cell Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary) ; Clostridium butyricum M588 (Primary) ; Nivolumab (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use

Most Recent Events

05 Jan 2026 Planned End Date changed from 25 Oct 2025 to 27 Jan 2026.
05 Jan 2026 Planned primary completion date changed from 25 Oct 2025 to 27 Jan 2026.
30 Apr 2025 Results investigating the prognostic significance of circulating CD5+ B cells in mRCC patients treated with cabozantinib/nivolumab with or without CBM58 presented at the 116th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com